PLN 43.6
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Urteste S.A. focuses on the investigation and development of diagnostic solutions designed to detect various forms of cancer. Their portfolio includes testing methods for a wide range of malignancies affecting organs such as the pancreas, prostate, kidneys, colon, liver, biliary system, stomach, lungs, esophagus, ovaries, endometrium, blood, breasts, and the nervous system. This enterprise, based in Gdansk, Poland, commenced its operations in 2021.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is trading at neutral levels on P/FCF
Data is available to registered users only